CDavid Nicholson - Allergan Plc Executive Vice President, Chief R&D Officer

<div class='circular--portrait' style='background:#347AFC;color: #ffffff;font-size:4em;padding-top: 25px;;'>AP</div>
AGN -- USA Stock  

Earnings Report: 4th of August 2020  

  President
Dr. C. David Nicholson is Chief RD Officer of the company since March 2015
Age: 63  President Since 2015  Ph.D    
862 261 7000  http://www.allergan.com
Nicholson is the Chief R&D Officer of Allergan and has served in this role since March 2015. He joined Allergan as Senior Vice President, Global Brands R&D in August 2014. Previously, he served as Chief Technology Officer and EVP, R&D for Bayer CropScience from March 2012 to August 2014; Vice President of Licensing and Knowledge Management at Merck from 2009 to December 2011; and Senior Vice President, responsible for Global Project Management and Drug Safety at ScheringPlough from 2007 to 2009. From 1988 to 2007, Dr. Nicholson held various leadership positions at Organon, where he most recently served as Executive Vice President, Research & Development and was a member of the company?s Executive Management Committee. He received a B.Sc. from the University of Manchester and his Ph.D. from the University of Wales.

Allergan Plc Management Efficiency

Allergan Plc has Return on Asset of (0.0564) % which means that on every $100 spent on asset, it lost $0.0564. This is way below average. In the same way, it shows return on shareholders equity (ROE) of (0.0913) %, meaning that it generated no profit with money invested by stockholders. Allergan Plc management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities.
The company has 23.08 B in debt with debt to equity (D/E) ratio of 39.4, demonstrating that the company may be unable to create cash to meet all of its financial commitments. Allergan Plc has a current ratio of 0.98, suggesting that it has not enough short term capital to pay financial commitments when the payables are due.

Similar Executives

Showing few of many executives

PRESIDENT Since

Charles WagnerVertex Pharmaceuticals Incorpor
2019
Michael GoettlerPfizer Inc
2019
Umang VohraDr Reddys Laboratories
2013
Albert BourlaPfizer Inc
2020
Christopher FenimoreRegeneron Pharmaceuticals
2017
Freda LewisHallPfizer Inc
2010
Thomas GraneyVertex Pharmaceuticals Incorpor
2017
Saumen ChakrabortyDr Reddys Laboratories
2018
Stefan WeiskopfZoetis Inc
2013
Lidia FonsecaPfizer Inc
2019
Angela HwangPfizer Inc
2019
Louis YuPerrigo Company Plc
2013
Michael PartridgeVertex Pharmaceuticals Incorpor
N/A
Samiran DasDr Reddys Laboratories
2016
Dawn RogersPfizer Inc
2019
Jatin ShahPerrigo Company Plc
2005
Raghav ChariDr Reddys Laboratories
2013
John GrayVertex Pharmaceuticals Incorpor
2019
J RamachandranDr Reddys Laboratories
2016
Jay MarkowitzRegeneron Pharmaceuticals
2017
Laurie OlsonPfizer Inc
2017

Company Summary

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. As of May 8, 2020, Allergan plc operates as a subsidiary of AbbVie Inc. Allergan Plc operates under Drug Manufacturers - General classification in USA and is traded on BATS Exchange. It employs 17400 people.Allergan Plc (AGN) is traded on New York Stock Exchange in USA and employs 17,400 people.

Allergan Plc Leadership Team

Matthew Walsh, Chief Financial Officer, Executive Vice President
Robert Bailey, Chief Legal Officer and Corporate Secretary
Robert Stewart, Executive VP and President of Generic and Global Operations
Ronald Taylor, Independent Director
Adriane Brown, Independent Director
William Meury, Executive Vice President, Chief Commercial Officer
Brenton Saunders, Chairman of the Board, President, Chief Executive Officer
Wayne Swanton, Executive Vice President - Global Operations
Robert Hugin, Independent Director
Nicholson, Chief R&D Officer
Christopher Bodine, Independent Director
Karen Ling, Chief Human Resource Officer, Executive Vice President
Michael Gallagher, Lead Independent Director
Paul Bisaro, Executive Chairman
Thomas Freyman, Independent Director
Catherine Klema, Lead Independent Director
James DArecca, Chief Accounting Officer
Christopher Coughlin, Lead Independent Director
Nesli Basgoz, Independent Director
Philippe Schaison, Executive Vice President and President Allergan Medical
Maria Hilado, CFO and Executive VP
Joseph Boccuzi, Independent Director
Patrick OSullivan, Independent Director
Fred Weiss, Independent Director
A Bailey, Executive Vice President, Chief Legal Officer and Corporate Secretary
Alex Kelly, Chief Communications Officer
CDavid Nicholson, Executive Vice President, Chief R&D Officer
Carol Davidson, Independent Director
Michael Greenberg, Independent Director
Ron Taylor, Independent Director
Jonathon Kellerman, Executive Vice President Chief Compliance Officer
Paul Navarre, Executive Vice President and President International Brands
James Bloem, Independent Director
Karina Calzadilla, IR Contact Officer
Peter McDonnell, Independent Director

Stock Performance Indicators

Did you try this?

Run Idea Breakdown Now

   

Idea Breakdown

Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
All  Next Launch Module

Allergan Plc Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Allergan Plc and Vertex Pharmaceuticals. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Please continue to Trending Equities. Please also try Analyst Recommendations module to analyst recommendations and target price estimates broken down by several categories.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page